The study was designed to analyse risk factors of venous thromboembolism (VTE), elucidate the role of genetic forms of thrombophilia and antiphospholipid syndrome (APS) in pathogenesis of VTE during pregnancy. 38 pregnant patients with VTE (group I) and 35 healthy pregnant women (group 2, controls) were screened for genetic thrombophilia and antiphospholipid antibodies (APA). Deep vein and ovarian vein thrombosis was diagnosed in 21 and 1 patients of group 1 respectively. VTE occurred in 15 on weeks 20-38 of pregnancy and in 12 in the postpartum period. 38 and 59% of the patients had VTE in their hereditary and obstetric histories respectively. Multigenic thrombophilia was recorded in all patients with VTE (4-6 mutations including homozygous ones), combined defects of fibrinolysis in 86%, and APA in 59%. Multigenic thrombophilia occurred in 20% of the healthy women while APA were not detected. It is concluded that thrombophilia may be an essential pathogenetic mechanism of thromboembolism during pregnancy. Women with pregnancy-associated thromboembolism, thromboembolism in personal or family history, and with the history of obstetric complications should be screened for thrombophilia.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients vte
12
thrombophilia antiphospholipid
8
multigenic thrombophilia
8
vte
6
thrombophilia
6
[pathogenesis prevention
4
prevention thromboembolic
4
thromboembolic complications
4
complications obstetric
4
obstetric practice]
4

Similar Publications

Venous thromboembolism (VTE) treatment with apixaban uses a higher 10 mg twice daily regimen for 7 days (lead-in therapy). But, in patients with initial parenteral anticoagulation treatment or those with higher bleeding risk, clinicians may not always adhere to the full 7-day lead-in duration. This retrospective cohort study included adult patients admitted to the Veterans Affairs Health care System from January 2011 to April 2022, who received at least 24 hours of parenteral anticoagulation followed by lead-in apixaban therapy for VTE.

View Article and Find Full Text PDF

Introduction: Preoperative patients with knee osteoarthritis have a significantly increased risk of venous thromboembolism (VTE). While the Caprini risk assessment model offers some clinical guidance in predicting deep vein thrombosis (DVT), it has a relatively low predictive accuracy. Enhancing the model by integrating biomarkers, such as D-dimers, can potentially improve its accuracy.

View Article and Find Full Text PDF

Background: Cancer-associated thromboembolism has been thoroughly investigated in previous studies, and direct oral anticoagulants (DOACs) were established for the treatment and prevention of venous thromboembolism (VTE). However, the risks of cancer-associated arterial thromboembolism (ATE) and the efficacy of DOACs remain unclear.

Objectives: To evaluate the risk factors and the clinical activity of edoxaban (EDO) for the prevention of ATE in patients with advanced lung cancer.

View Article and Find Full Text PDF

Deep vein thrombosis (DVT) is a leading cause of death disability. DVT can be classified based on the location and extent of the clot into isolated distal DVT (iDDVT), isolated proximal DVT (iPDVT), or mixed DVT. The aim of this study is to explore the baseline characteristics and clinical outcomes of patients with different types of DVT.

View Article and Find Full Text PDF

Objective: Obesity is a risk factor for joint arthroplasty complications. With this systematic review and meta-analysis, we assessed whether a positive history of bariatric surgery influences postoperative outcomes in patients undergoing various types of joint arthroplasty.

Methods: We conducted a comprehensive search database such as Scopus, PubMed, Medline Ovid, CNKI, and CENTRAL for studies comparing outcomes between patients undergoing arthroplasty with and without a history of bariatric surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!